Recruiting

New radioactive treatment for advanced neuroendocrine tumors that have stopped responding to prior therapy

Plain-English translation of NCT05477576 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated July 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing , a new radioactive medication designed to treat advanced neuroendocrine tumors — rare cancers that grow slowly in the digestive system or pancreas. You would be eligible if your tumor has grown back or worsened after receiving a previous radioactive treatment called Lutetium-177. The study will compare how well this medication works compared to standard treatments your doctor might normally choose.

Some patients with advanced neuroendocrine tumors stop responding to the standard radioactive therapy they receive first. Doctors need better options for these patients, and this medication represents a new approach using a different type of radioactive element to target and kill cancer cells.

Do you qualify?

You likely qualify if…

you have been diagnosed with a grade 1 or 2 neuroendocrine tumor in your digestive system or pancreas that cannot be surgically removed
your tumor has grown or progressed after receiving 2 to 4 cycles of Lutetium-177 labeled therapy, and your cancer was controlled for at least 6 months after that treatment
your kidney function is adequate, with a glomerular filtration rate of at least 60 mL/min/1.73 m2
your blood cell counts (hemoglobin, white blood cells, and platelets) are at acceptable levels to safely receive treatment
you are in relatively good overall health, with an Eastern Cooperative Oncology Group performance status of 0 to 2

You likely don't qualify if…

you have had a previous procedure called radioembolization to treat your cancer
you have significant heart disease, including heart failure, a low ejection fraction, or abnormal heart rhythm patterns
you have uncontrolled high blood pressure (above 140/90 mmHg) despite taking at least three blood pressure medications
you have uncontrolled diabetes with a hemoglobin A1C of 8% or higher
you have a history of liver cirrhosis or have received a liver transplant

What participation looks like

You will be randomly assigned to receive either or one of several standard treatments that your doctor chooses. The trial has two parts: Part 1 determines the safest dose of the new medication, and Part 2 compares directly against standard care options. You will have regular visits for physical exams, blood tests, imaging scans to measure your tumor, and heart monitoring to ensure the treatment is working and safe for you.

AI-generated summary from trial data · Jul 15, 2026 · Not medical advice

Trial locations(54 sites)

United States

Research Facility, Phoenix, Arizona

Research Facility, Duarte, California

Research Facility, Irvine, California

Research Facility, Los Angeles, California

Research Facility, Palo Alto, California